7ZV5
Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 4
Summary for 7ZV5
| Entry DOI | 10.2210/pdb7zv5/pdb |
| Related PRD ID | PRD_002413 |
| Descriptor | 3C-like proteinase nsp5, inhibitor TRIP5, DIMETHYL SULFOXIDE, ... (4 entities in total) |
| Functional Keywords | sars cov-2, 3cl, main protease, antiviral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 More |
| Total number of polymer chains | 2 |
| Total formula weight | 34352.24 |
| Authors | Rahimova, R.,Di Micco, S.,Marquez, J.A. (deposition date: 2022-05-13, release date: 2022-11-30, Last modification date: 2024-01-31) |
| Primary citation | Di Micco, S.,Rahimova, R.,Sala, M.,Scala, M.C.,Vivenzio, G.,Musella, S.,Andrei, G.,Remans, K.,Mammri, L.,Snoeck, R.,Bifulco, G.,Di Matteo, F.,Vestuto, V.,Campiglia, P.,Marquez, J.A.,Fasano, A. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Eur.J.Med.Chem., 244:114857-114857, 2022 Cited by PubMed Abstract: Although vaccines are greatly mitigating the worldwide pandemic diffusion of SARS-Cov-2, therapeutics should provide many distinct advantages as complementary approach to control the viral spreading. Here, we report the development of new tripeptide derivatives of AT1001 against SARS-CoV-2 M. By molecular modeling, a small compound library was rationally designed and filtered for enzymatic inhibition through FRET assay, leading to the identification of compound 4. X-ray crystallography studies provide insights into its binding mode and confirm the formation of a covalent bond with M C145. In vitro antiviral tests indicate the improvement of biological activity of 4 respect to AT1001. In silico and X-ray crystallography analysis led to 58, showing a promising activity against three SARS-CoV-2 variants and a valuable safety in Vero cells and human embryonic lung fibroblasts. The drug tolerance was also confirmed by in vivo studies, along with pharmacokinetics evaluation. In summary, 58 could pave the way to develop a clinical candidate for intranasal administration. PubMed: 36332548DOI: 10.1016/j.ejmech.2022.114857 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.999 Å) |
Structure validation
Download full validation report
